Detailed guide: Notify the MHRA about a clinical investigation for a medical device

Medicines Healthcare Products Regulatory Agency

January 14
11:20 2021

You may need to carry out a clinical investigation as part of the process to obtain a UKCA / CE / CE UKNI marking for your medical device. You must inform the MHRA if you are planning to do this at least 60 days before starting your investigation.

How to notify the MHRA of your clinical investigation

A notification to the MHRA will not be required for medical devices that are UKCA / CE / CE UKNI marked for the purpose that is under investigation.

If possible, please provide the MHRA with advanced notice of your intention to submit a clinical investigation by emailing with some basic details about the investigational device, the intended population, the type of study, and estimated application date. Please provide as much notice as possible. An advanced notice is helpful to the MHRA, however is not a substitute for the formal clinical investigation notification.

You need to prepare your documents before you notify the MHRA of a proposed clinical investigation.

Follow the guidance on compiling a submission (PDF, 258KB, 15 pages) and guidance for manufacturers (PDF, 418KB, 18 pages) when preparing your notification application.

Applications are submitted electronically using the Integrated Research Application System (IRAS)


The Medical Devices (Fees Amendment) Regulations 2017 came into force on 1 April 2017. These regulations include the introduction of new fees for amendments to clinical investigations.

You do not need to attach proof of payment to applications. You will receive an invoice to allow you to make payment for the correct amount once your application has been validated.

Information on how to notify the MHRA about an amendment for a clinical investigation can be found below under Amendments. Information on the applicable fees are available using the link below.

Please note: The fee rate is based on a single investigational device being used in a study. Where two or more investigational devices are being used and there is no functional relationship between them, the fee will be increased to reflect the additional workload to the MHRA. For further clarification, contact

See fees for clinical investigationsand make a payment to the MHRA for your notification before submitting it if you havent already.


When the MHRA has received your documents and validated them, we will write to you within 5 working days to confirm that the 60-day assessment has started or we will let you know if there are any issues. If there are any issues raised, the 60-day assessment will start when we receive a valid response. Day 1 of the 60 days is taken as being the first working day that follows the date of receipt of a valid Notification.

During the assessment, experts will assess the safety and performance of your device as well as the design of the clinical investigation to be carried out. The MHRA will write to you if we require further information. It is essential that you contact the MHRA as soon as possible if you require clarification. Where possible we will arrange a teleconference for a better understanding and to find a resolution within the 60-day assessment time, if there are possible grounds for objection.

A letter will be sent to you by the 60th day with a decision (objection or no objection) as to whether or not you can carry out the proposed clinical investigation.

Coordinated assessment pathway pilot

The MHRA is working with the Health Research Authority (HRA) to pilot a new coordinated assessment pathway which will streamline the review of clinical investigations involving medical devices.

During this phase of the pilot, the MHRA Medical Devices review and the Research Ethics Committee (REC) review will be done in parallel and information will be shared. There will be no change to the application forms or method of submission.

Taking part in the pilot

If you are interested in taking part in the pilot, you first need to tell us by emailing with MHRA/HRA Coordinated assessment pathway pilot in the subject line. This should be done before submitting any applications and we will then send you further guidance.

For your study to be eligible for the pilot:

  • the lead site should be in England
  • you should contact the MHRA prior to any submission to REC or MHRA

For this phase of the pilot there are some exclusions. We cannot include clinical investigations that:

  • involve participants who are adults lacking capacity
  • are a combined trial of an investigational medicinal product and an investigational medical device


Once youve received a letter of no objection from us, you must notify the MHRA of all proposed amendments to the investigation. You must wait until we send you another letter of no objection before you implement the changes.

You must tell us about any changes made to:

  • the device under investigation
  • study documentation, including the clinical investigation plan
  • investigators or investigating institutions
  • changes requested by an ethics committee

If you dont tell us about proposed amendments you could be liable to prosecution.

When you notify us of amendments, we need the following information:

  • covering letter with:
    • the MHRA reference number for the clinical investigation
    • a table with a summary of each proposed change with the reason for each change
  • red lined (showing changes being made) and clean copies of all amended study documentation

  • a signed statement by, or on behalf of, the manufacturer that the proposed change(s) do not predictably increase the risk to the patient, user or third party

  • details of who to invoice (full company name, address and registered tax/VAT number)

You can send us the amendments by email unless the files are too big, in which case contact us at to request a link for uploading the documents (see Fees above).

You will need to pay a fee for amendments to clinical investigations.

Related Articles


  1. We don't have any comments for this article yet. Why not join in and start a discussion.

Write a Comment

Your name:
Your email:

Post my comment

Recent Comments

Follow Us on Twitter

Share This

Enjoyed this? Why not share it with others if you've found it useful by using one of the tools below: